Results 31 to 40 of about 399,014 (392)

Identification of Dihydrofuro[3,4- d]pyrimidine Derivatives as Novel HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors with Promising Antiviral Activities and Desirable Physicochemical Properties.

Journal of Medicinal Chemistry, 2019
To address drug resistance to HIV-1 non-nucleoside reverse transcriptase inhibitors (NNRTIs), a series of novel diarylpyrimidine (DAPY) derivatives targeting "tolerant region I" and "tolerant region II" of the NNRTIs binding pocket (NNIBP) were designed ...
Dongwei Kang, Heng Zhang, Zhao Wang, Tong Zhao, Tiziana Ginex, F. Luque, Yang Yang, Gaochan Wu, Da Feng, Fenju Wei, Jian Zhang, E. De Clercq, C. Pannecouque, Chin-Ho Chen, K. Lee, N. A. Murugan, T. Steitz, P. Zhan, Xinyong Liu   +18 more
semanticscholar   +1 more source

Second-line antiretroviral therapy in resource-limited settings: the experience of Médecins Sans Frontières [PDF]

, 2008
OBJECTIVES: To describe the use of second-line protease-inhibitor regimens in Médecins Sans Frontières HIV programmes, and determine switch rates, clinical outcomes, and factors associated with survival.
Alexandra Calmy, Boyd, Braitstein, Calmy, Calmy, Chaiwarith, Colebunders, Daniel O'Brien, Ferradini, Gallant, Galárraga, Ivers, Laurent, Ledergerber, Mar Pujades-Rodríguez, Mocroft, Nicastri, Orrell, Pierre Humblet, Renaud-Théry, Srasuebkul, Sungkanuparph, Vasan, Vekemans, Walmsley   +24 more
core   +2 more sources

Antiretroviral treatment can affect the release of NO and EDCF, but EDH in rat arteries [PDF]

, 2012
This journal suppl. entitled: EDHF 2012 - 10th Anniversary MeetingDespite improving clinical outcomes, highly active antiretroviral therapy (HAART) is an independent potential risk factor for cardiovascular diseases.
Lee, SS, Leung, SWS, Nejad, A, Vanhoutte, PM   +3 more
core   +1 more source

The Journey of HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) from Lab to Clinic.

Journal of Medicinal Chemistry, 2018
Human immunodeficiency virus (HIV) infection is now pandemic. Targeting HIV-1 reverse transcriptase (HIV-1 RT) has been considered as one of the most successful targets for the development of anti-HIV treatment.
V. Namasivayam, Murugesan Vanangamudi, Victor G. Kramer, Sonali Kurup, P. Zhan, Xinyong Liu, J. Kongsted, S. Byrareddy   +7 more
semanticscholar   +1 more source

Anti-HIV-1 activity of benzothiadiazine dioxide [PDF]

, 2013
Antiviral assays carried out on the potent benzothiadiazine dioxide (BTD) human cytomegalovirus (HCMV) inhibitors have led us to find marginal but selective anti-HIV-1 activity.
Balzarini, Jan, Castro, Ana, De Clercq, Erik, Gil, Carmen, Martínez, Ana, Pannecouque, C., Pérez, Concepción, Witvrouw, M.   +7 more
core   +2 more sources

Drogas anti-VIH: passado, presente e perspectivas futuras Drugs anti-HIV: past, present and future perspectives

Química Nova, 2003
Currently available anti-HIV drugs can be classified into three categories: nucleoside analogue reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs) and protease inhibitors (PIs).
Marcus Vinícius Nora de Souza, Mauro Vieira de Almeida   +1 more
doaj   +1 more source

Potent nonnucleoside reverse transcriptase inhibitors target HIV-1 Gag-Pol. [PDF]

PLoS Pathogens, 2006
Nonnucleoside reverse transcriptase inhibitors (NNRTIs) target HIV-1 reverse transcriptase (RT) by binding to a pocket in RT that is close to, but distinct, from the DNA polymerase active site and prevent the synthesis of viral cDNA.
Anna Figueiredo, Katie L Moore, Johnson Mak, Nicolas Sluis-Cremer, Marie-Pierre de Bethune, Gilda Tachedjian   +5 more
doaj   +1 more source

High-level resistance to non-nucleos(t)ide reverse transcriptase inhibitor based first-line antiretroviral therapy in Ghana; A 2017 study

Frontiers in Microbiology, 2022
Expanding access to effective antiretroviral therapy (ART) is a major tool for management of Human Immunodeficiency Virus (HIV) infection. However, rising levels of HIV drug-resistance have significantly hampered the anticipated success of ART in persons
Prince Kofi Parbie, Christopher Zaab-Yen Abana, Christopher Zaab-Yen Abana, Christopher Zaab-Yen Abana, Dennis Kushitor, Theodore Worlanyo Asigbee, Theodore Worlanyo Asigbee, Nana Afia Asante Ntim, Nana Afia Asante Ntim, Gifty Addo-Tetebo, Maclean Richard Darko Ansong, Sampson Badu Ofori, Taketoshi Mizutani, Lucky Ronald Runtuwene, Masako Nishizawa, Koichi Ishikawa, Hiroshi Kiyono, Hiroshi Kiyono, Hiroshi Kiyono, William Kwabena Ampofo, Tetsuro Matano, Tetsuro Matano, Tetsuro Matano, Evelyn Yayra Bonney, Tadashi Kikuchi   +24 more
doaj   +1 more source

A Review of Electroanalytical Techniques for Determination of Anti-HIV Drugs

International Journal of Electrochemistry, 2011
Until now after the human immunodeficiency virus (HIV) was discovered as the then tentative aetiological agent of acquired immune deficiency syndrome (AIDS), exactly 25 anti-HIV compounds have been formally approved for clinical use in the treatment of ...
Burçin Bozal, Bengi Uslu, Sibel A. Özkan   +2 more
doaj   +1 more source

HIV - recentes avanços na pesquisa de fármacos HIV - highlights in drug research

Química Nova, 2008
The development of new antiretroviral drugs is a dynamic process that is continuously fueled by identification of new molecular targets and new compounds for know targets.
Wilson Cunico, Claudia R. B. Gomes, Walcimar T. Vellasco Junior   +2 more
doaj   +1 more source